Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-CTL-associated antigen 4: are regulatory T cells a target?

× No keyword cloud information.

11 in total

1. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.

Authors: Alex B Blair; Lei Zheng
Journal: Chin Clin Oncol Date: 2017-06

Review 2. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?

Authors: Julie R Brahmer
Journal: Semin Oncol Date: 2013-12-12 Impact factor: 4.929

3. Ipilimumab: its potential in non-small cell lung cancer.

Authors: Pascale Tomasini; Nataliya Khobta; Laurent Greillier; Fabrice Barlesi
Journal: Ther Adv Med Oncol Date: 2012-03 Impact factor: 8.168

Review 4. Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors: Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal: Nat Rev Cancer Date: 2015-08 Impact factor: 60.716

5. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.

Authors: Nicola Mozzillo; Paolo Ascierto
Journal: Clin Exp Metastasis Date: 2012-07-01 Impact factor: 5.150

6. ANALYSIS OF DENDRITIC CELL STIMULATION UTILIZING A MULTI-FACETED NANOPOLYMER DELIVERY SYSTEM AND THE IMMUNE MODULATOR 1-METHYL TRYPTOPHAN.

Authors: Kevin P Nikitczuk; Edmund C Lattime; Rene S Schloss; Martin L Yarmush
Journal: Nano Life Date: 2010-09-01

7. A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

Authors: Susan M Hiniker; Daniel S Chen; Sunil Reddy; Daniel T Chang; Jennifer C Jones; Joseph A Mollick; Susan M Swetter; Susan J Knox
Journal: Transl Oncol Date: 2012-12-01 Impact factor: 4.243

8. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.

Authors: Paolo A Ascierto; Maria Napolitano; Egidio Celentano; Ester Simeone; Giusy Gentilcore; Antonio Daponte; Mariaelena Capone; Corrado Caracò; Rosa Calemma; Gerardo Beneduce; Margherita Cerrone; Vincenzo De Rosa; Giuseppe Palmieri; Giuseppe Castello; John M Kirkwood; Francesco M Marincola; Nicola Mozzillo
Journal: J Transl Med Date: 2010-08-16 Impact factor: 5.531

9. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma.

Authors: Claire Verschraegen
Journal: Cancer Manag Res Date: 2012-01-18 Impact factor: 3.989

Review 10. The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.

Authors: Emmanuel Gabriel; Joseph Skitzki
Journal: Cancers (Basel) Date: 2015-07-01 Impact factor: 6.639